Cytk News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cytk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cytk Today - Breaking & Trending Today

Fisher Asset Management LLC Makes New $44.75 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)

Fisher Asset Management LLC purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 535,954 shares of the biopharmaceutical company’s stock, valued at approximately $44,747,000. Fisher Asset Management LLC owned approximately 0.55% of Cytokinetics […] ....

Johnt Henderson , Fady Ibraham Malik , Td Asset Management Inc , Morgan Stanley , Legato Capital Management , Securities Exchange Commission , Cytokinetics Company Profile , Cytokinetics Incorporated , Vanguard Group Inc , Fisher Asset Management , Free Report , Asset Management , Management Inc , Minvest Partners , Get Free Report , Director John , Exchange Commission , Ibraham Malik , Cytokinetics Daily , Nasdaq Cytk , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Brokerages

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the fifteen ratings firms that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price objective […] ....

Johnt Henderson , Charles Schwab Investment Management Inc , Norges Bank , Cytokinetics Incorporated , Needham Company , Vanguard Group Inc , First Turn Management , Morgan Stanley , Get Free Report , Director John , Turn Management , Schwab Investment Management , Get Free , Cytokinetics Daily , Nasdaq Cytk ,

2,439 Shares in Cytokinetics, Incorporated (NASDAQ:CYTK) Purchased by Sage Rhino Capital LLC

Sage Rhino Capital LLC acquired a new position in shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,439 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. Several other […] ....

Fady Ibraham Malik , Johnt Henderson , Cytokinetics Company Profile , Sage Rhino Capital , Vanguard Group Inc , Legato Capital Management , Exchange Commission , Securities Exchange Commission , Needham Company , Td Asset Management Inc , Cytokinetics Incorporated , Free Report , Management Inc , Minvest Partners , Get Free Report , Director John , Ibraham Malik , Cytokinetics Daily , Nasdaq Cytk , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Needham & Company LLC Reaffirms Buy Rating for Cytokinetics (NASDAQ:CYTK)

Needham & Company LLC reissued their buy rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research report released on Tuesday morning, Benzinga reports. The firm currently has a $108.00 price objective on the biopharmaceutical company’s stock. Other equities analysts also recently issued reports about the company. Oppenheimer reiterated an outperform rating and […] ....

Los Angeles , United States , Fady Ibraham Malik , Roberti Blum , Raymond James , Cytokinetics Company Profile , Needham Company , Cytokinetics Incorporated , Vanguard Group Inc , Fisher Asset Management , Perceptive Advisors , Los Angeles Capital Management , Securities Exchange Commission , Virtu Financial , Free Report , Moderate Buy , Stock Down , Get Free Report , Ibraham Malik , Exchange Commission , Angeles Capital Management , Asset Management , Cytokinetics Daily , Nasdaq Cytk , Reiterated Rating , Needham Company Llc ,

Cytokinetics, Incorporated (NASDAQ:CYTK) Given Consensus Rating of "Moderate Buy" by Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average twelve-month […] ....

United States , Fady Ibraham Malik , Raymond James , Johnt Henderson , Securities Exchange Commission , Quadrant Capital Group , Morgan Stanley , Cytokinetics Incorporated , Financial Services Group Inc , Mutual Of America Capital Management , Needham Company , Get Free Report , Marketbeat Ratings , Ibraham Malik , Exchange Commission , Director John , State Retirement , Pension System , Capital Group , Financial Advisors , America Capital Management , Services Group , Get Free , Cytokinetics Daily , Nasdaq Cytk ,